Neural Mechanisms of Intermittent Theta Burst Stimulation in the Core Depression Network

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-26

Study Completion Date

2026-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Repetitive Transcranial magnetic stimulation (TMS) uses magnetic fields to modulate brain activity. A novel form of repetitive TMS (rTMS), intermittent theta burst stimulation (iTBS), has emerged as a promising new treatment for depression. This technique may be advantageous due to its very short duration and potentially stronger effect on brain activity in comparison with standard rTMS. However, the exact effect of iTBS on the activity of the brain in clinical populations remains poorly understood. This project aims to improve understanding of the mechanisms of action of iTBS by comparing its neuronal effect to sham treatment in 22 individuals with a diagnosis of major depressive episode, using positron emission tomography (PET) and magnetic resonance imaging (MRI) in a double-blind cross-over experiment, followed by a 6-week daily treatment course of iTBS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparing Uni- and Bi-lateral TBS in Major Depression

NCT04142996

Major Depressive Episode

RECRUITING NA

Comparing the Efficacy of fMRI-Guided vs. Standard iTBS in Treating Depression

NCT06152705

Depression Depressive Disorder, Major Depressive Episode

RECRUITING NA

Accelerated Intermittent Theta Burst Stimulation for Depressed Patients During the Covid-19 Pandemic

NCT04935489

Treatment Resistant Depression

COMPLETED NA

Comparing the Efficacy of Accelerated vs. Standard fMRI-guided iTBS in Treating Adolescents Depression

NCT06528938

Depression Depressive Disorder, Major

RECRUITING NA

Pilot Study Comparing 10hz vs Theta Burst Stimulation

NCT02800226

Major Depressive Disorder

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Typical clinical rTMS treatment is delivered on the left dorsolateral prefrontal cortex (DLPFC) at a 10 Hz frequency for 30-45 minutes to increase cortical excitability which will outlast the duration of stimulation. The treatment involves daily sessions that are applied over a four to six-week period. Intermittent theta burst stimulation (iTBS) is a novel refinement of conventional rTMS. iTBS consists of bursts of 3 stimulations at 50 Hz at theta frequency (5 Hz). However, instead of 30-min treatment sessions, iTBS has comparable clinical efficacy with only 3 minutes treatment sessions. Because iTBS is a novel technique, much of its effects on the brain are currently unknown. However, since it is a modified rTMS protocol, it is assumed that its neuronal effects are comparable.

Therapeutic effects of rTMS are thought to be related to its effects on the subgenual anterior cingulate cortex (sgACC; Broadman area 25). In depression, metabolic activity of the sgACC is increased (measured as increase of 18F-labeled fluorodeoxyglucose (\[18F\]FDG) uptake with positron emission tomography (PET)). Importantly, the metabolic activity of the sgACC appears to be a general marker for treatment response, e.g. \[18F\]FDG uptake is decreased in response to antidepressant medications or deep brain stimulation. In addition to resting state functional MRI, diffusion weighted imaging has been used to study TMS targets, but this technique has never been used for testing targets for treating depression.

Currently, the system level mechanisms of action of iTBS in depression patients are completely unexplored. Based on prior research the investigators hypothesize that 1) a single session of iTBS will decrease \[18F\]FDG uptake in the sgACC and 2) the magnitude of decrease is related to the connectivity between the target site and the sgACC. This study will establish the system level mechanisms of action of iTBS, paving a way to improve clinical treatment. This study will also develop connectivity measures that can be used to improve iTBS targeting (i.e. choose iTBS target based on sgACC connectivity) and predict treatment response (i.e. predict iTBS treatment response in patients based on sgACC connectivity).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

The study will be divided in two main parts. In Part I, we will use a randomized cross-over double-blinded design. The order of the iTBS conditions (active vs. sham) will be counterbalanced across participants. In part II, participants will receive a 6-week daily iTBS open-label treatment. Participants and research team members performing iTBS and analyses will be blind to the stimulation condition for Part I of the study. The order of the conditions will be determined by a separate research team member that will not be performing iTBS or analyses. Participants will be told that there is a sham condition, for Part I of the trial. The master randomization list was created by a scientist of the research centre that is not involved in the research project.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sham iTBS/Active iTBS

Intermittent Theta Burst Stimulation (iTBS) or realistic sham iTBS will be applied to the left DLPFC. Both sessions will be one week apart.

Group Type SHAM_COMPARATOR

Theta burst stimulation

Intervention Type DEVICE

Cool B65 active/placebo coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)

Active iTBS

Intermittent Theta Burst Stimulation (iTBS) will be applied to the left DLPFC. Participants will receive daily sessions (on weekdays) for 6 weeks.

Group Type ACTIVE_COMPARATOR

Theta burst stimulation

Intervention Type DEVICE

Cool B70 coil (left DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Theta burst stimulation

Cool B65 active/placebo coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)

Intervention Type DEVICE

Theta burst stimulation

Cool B70 coil (left DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men or women aged 18 to 55 years of age
* Mini-International Neuropsychiatric Interview-confirmed diagnosis of MDD, as a single or recurring episode
* Symptoms of MDD have not improved after ≥ 1 but ≤ 7 adequate dose(s) of antidepressant trial(s) in the current depressive episode
* A baseline score of ≥ 15 on the 17-item Hamilton Rating Scale for Depression (HRSD-17)
* Have received a stable antidepressant regimen for at least four weeks prior to entering trial
* Are voluntary and competent to consent to study
* Can speak and read English

Exclusion Criteria

* Current or past (\< 3 months) substance (including nicotine) or alcohol abuse/dependence, as defined in DSM-5 criteria
* Positive urine test for illegal substances, cannabis, or cotinine
* Suicide attempt in the past three months and/or active suicidal intent
* Pregnancy (confirmed by urine test) and/or lactation
* Psychotic features in the current episode
* Any comorbid mental health disorders (including, but not limited to lifetime history of psychotic disorders, OCD, PTSD and/or bipolar I or II disorder) with the exception of anxiety/panic disorders and ADHD
* Significant unstable medical or neurologic illness confirmed by medical history and blood test at baseline (e.g. uncontrolled diabetes, or renal dysfunction)
* Organic cause to the depressive symptoms (e.g. thyroid dysfunctions), as ruled out by the referring physician
* Contraindication for TMS (e.g., personal history of epilepsy or convulsion, metallic head implant, pacemaker)
* Contraindication for MRI (e.g. metallic implant, claustrophobia)
* Have undergone a prior PET or SPECT research study
* ECT or rTMS treatment in the current depressive episode
* Benzodiazepine use
* Have a body mass index (BMI) higher then 35 or lower then 18
* Any other condition that, in the opinion of the investigators, would adversely affect the participant's ability to complete the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No